欢迎来到"The Pink Sheet"， 通过以下简单的注册程序，您能得到一份免费赠送的独家产业报道和同样免费定期全球医药最新信息提醒。

Thank you for your interest in the free report from “The Pink Sheet”, the leading regulatory and business publication for global biopharma executives. In this report, “The Pink Sheet” explores the key factors that will impact the commercial success of Amgen’s most important pipeline drug, osteoporosis therapy Prolia (denosumab). To receive instant access to the report, please fill out the form below.

 

If you do business in the U.S. or Europe, if you need to understand how U.S. FDA regulates the biopharma industry – from clinical trials to drug approvals to GMP enforcement - if you partner with multinational biopharma companies, then you need to read what your global peers read each and every week –  “The Pink Sheet”. Register for a FREE 30 day trial.

 

Find out why “The Pink Sheet” is read by U.S. FDA, and by executives at all the major biopharma companies, including Pfizer, GSK, Sanofi-Aventis, Novartis, Roche, AstraZeneca, J&J, Merck, Bayer and Takeda — register for a FREE 30 day trial.